Form 4: Xeris Biopharma Director John Johnson Acquires 50,000 Shares Through Restricted Stock Unit Award

Director John Johnson acquired 50,000 shares of Xeris Biopharma Holdings, Inc. through a restricted stock unit award.

Summary

• On June 5, 2024, John Johnson, a director of Xeris Biopharma Holdings, Inc., acquired 50,000 shares of common stock.
• The acquisition was made through a restricted stock unit (RSU) award under the company's 2018 Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of Xeris Biopharma's common stock.
• The shares will vest in full on the earlier of June 5, 2025, or the date of the company's next annual meeting of stockholders.
• Following the transaction, Johnson beneficially owns 890,983 shares of Xeris Biopharma common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of an insider transaction. The acquisition of shares by a director is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The shares acquired through the restricted stock unit award will vest on the earlier of June 5, 2025, or the date of the company's next annual meeting of stockholders.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates